LSDIF (Lucy Scientific Discovery) Total Receivables: $0.01 Mil (As of Dec. 2023)


What is Lucy Scientific Discovery Total Receivables?

Lucy Scientific Discovery LSDIF Total Receivables is $0.01 Mil as of Dec. 2023.

Lucy Scientific Discovery's Total Receivables for the quarter that ended in Dec. 2023 was $0.01 Mil.

Lucy Scientific Discovery Total Receivables Related Terms

Lucy Scientific Discovery Total Receivables Historical Data

* Premium members only.

The historical data trend for Lucy Scientific Discovery's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lucy Scientific Discovery Total Receivables Chart

Lucy Scientific Discovery Annual Data
Trend Jun21 Jun22 Jun23
Total Receivables
0.01 0.01 0.41

Lucy Scientific Discovery Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Total Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 0.04 0.04 0.41 0.01 0.01

Lucy Scientific Discovery Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables

Frequently Asked Questions Learn more about Total Receivables →
What does a Total Receivables of $0.01 Mil mean?
Lucy Scientific Discovery (LSDIF) has a Total Receivables of $0.01 Mil as of Dec. 2023. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Lucy Scientific Discovery and its competitors.
Is Lucy Scientific Discovery's Total Receivables too high?
Lucy Scientific Discovery's current Total Receivables is $0.01 Mil.
How does Lucy Scientific Discovery's Total Receivables compare to INQD and ZTS?
Lucy Scientific Discovery's Total Receivables of $0.01 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Receivables for a Drug Manufacturers company?
A good Total Receivables depends on the Drug Manufacturers industry context. However, Total Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Receivables mean?
A high Total Receivables can signal that a stock is expensive relative to its fundamentals. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Lucy Scientific Discovery and its competitors. Lucy Scientific Discovery's current Total Receivables is $0.01 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lucy Scientific Discovery stock overvalued right now?
Lucy Scientific Discovery (LSDIF) has a current Total Receivables of $0.01 Mil. The current Total Receivables is $0.01 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Receivables calculated?
Total Receivables is calculated from a company's financial statements. For Lucy Scientific Discovery (LSDIF), the current Total Receivables is $0.01 Mil as of Dec. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Lucy Scientific Discovery Business Description

Address 301-1321 Blanshard Street, Victoria, BC, CAN, V8W 0B6
Lucy Scientific Discovery Inc is an early-stage psychotropics contract manufacturing company focused on becoming the contract research, development, and manufacturing organization for the emerging psychotropics-based medicines industry. Its drug products are designed to treat a range of mental health and cognitive conditions.